Immunome Reports Third Quarter 2020 Financial Results and Significant Progress
– Completed $44.9M IPO in October –
– Identified COVID 19 Neutralizing antibodies –
– Significant progress made on lead programs, including IMM-BCP-01 for the treatment of COVID-19 in collaboration with US Department of Defense –